Home > News > Laboratory Diagnostics in Septic Disseminated Intravascular Coagulation
Haematology
Read Time: 5 mins

Laboratory Diagnostics in Septic Disseminated Intravascular Coagulation

Published Online: August 18th 2011 European Haematology, 2009;3(1):19-24 DOI: https://doi.org/10.17925/EOH.2009.03.1.19
Authors: Giuseppe Lippi, Gian Cesare Guidi
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

The diagnosis of septic disseminated intravascular coagulation (DIC) relies on clinical signs and symptoms, identification of the underlying disease and results of laboratory testing. Since no single test result alone can definitely establish or rule out the diagnosis, the laboratory diagnostics of septic DIC encompass a combination of tests for which simple diagnostic algorithms are now available. Global tests of haemostasis provide evidence of activation of blood coagulation and, ultimately, consumption of coagulation factors, but their diagnostic efficiency is as yet questionable. Fibrinolytic markers, namely D-dimer, reflect the extent of activation of both coagulation and fibrinolysis, so a normal value can be used in a ruling-out strategy. Decreased levels of the natural inhibitors are frequently observed in patients with septic DIC, but antithrombin and protein C measurements are not incorporated in any of the widely used diagnostic algorithms. Among the inflammatory biomarkers, procalcitonin is currently regarded as the gold standard to differentiate the type of infection and guide antibiotic therapy, but its clinical usefulness in identifying and predicting the outcome of patients with septic DIC is still circumstantial.

Keywords

Disseminated intravascular coagulation (DIC), diagnosis, haemostasis, infection, sepsis

Article:

Disseminated intravascular coagulation (DIC) is a systemic, life-threatening disease characterised by excess thrombin generation and simultaneous activation of the fibrinolytic system. The clinical condition that follows is characterised by the presence of various degrees of both intravascular coagulation and haemorrhage resulting from consumption of coagulation factors. According to the Subcommittee (SSC) on DIC of the International Society on Thrombosis and Haemostasis (ISTH), the pathology can be defined as an acquired syndrome characterised by the intravascular activation of coagulation with loss of localisation arising from different causes that can originate from and cause damage to the microvasculature and that, if sufficiently severe, can lead to organ dysfunction.1
Contrary to widespread belief, DIC should not be considered as a primary disease, but rather as one of the worst complications of several underlying illnesses. As such, DIC can arise from a variety of systemic or localised pathologies, involving most (if not all) organs and tissues. Systemic and persistent activation of blood coagulation may occur in patients with sepsis, severe infections, malignancies (solid tumours and myeloproliferative/lymphoproliferative malignancies), obstetric complications (amniotic fluid embolism, abruptio placentae, placenta previa, retained dead foetus syndrome), vascular disorders (vascular aneurysms, Kasabach-Merritt syndrome), severe organ injury (acute pancreatitis, hepatic failure), massive trauma, extensive burns, surgery and severe toxic (snake bites, drugs) or immunological reactions (haemolytic transfusion reaction, transplant rejection).2–4
Although the clinical spectrum of DIC is often heterogeneous and the balance between thrombosis (micro- or macrothrombosis) and bleeding (petechiae, ecchymoses, mucosal, skin and catheter haemorrhages) varies widely on an individual basis and according to the underlying cause, all bodily organs can be affected, such that multiorgan failure (MOF) is often a catastrophic end-point. In its most severe form, the combination of thrombosis and haemorrhage may trigger Waterhouse-Friderichsen syndrome (septicaemia and acute adrenal insufficiency), which is frequently observed in patients with fulminant meningococcal septicaemia.5
The magnitude of the mutual clinical relationship between sepsis and DIC is reflected by epidemiological data attesting that DIC is a rather frequent complication in patients with sepsis (DIC is observed in up to 50% of patients with sepsis and is a strong predictor of mortality) and, on the other side of the coin, sepsis is by far the most frequent underlying condition identified in patients with DIC.6 Although lipopolysaccharide (LPS), conventionally referred to as endotoxin, is recognised as the most potent microbial mediator implicated in the pathogenesis of sepsis and septic shock,7 it is not alone as a cause of the worst overall complications (MOF and DIC).8 Cell membrane components of several micro-organisms (LPS or endotoxin) or bacterial exotoxins, such as staphylococcal α-haemolysin, can in fact induce a generalised inflammatory response through the activation of pro-inflammatory cytokines and thrombin generation by activation of the tissue factor/factor VIIa pathway (see Figure 1).
A second important mechanism triggering sepsis-related DIC is thought to be the translocation of cell membrane aminophospholipids from the inner to the outer leaflet, or their release into the bloodstream as a consequence of cell breakdown. This is commonplace in several forms of sepsis, since host cells may be injured or broken directly by the microrganisms, whereas bacterial cells may be destroyed by heat, antibodies or antibiotics;8 as such, it can be concluded that ‘all bugs bite equally’. In fact, although there is a widespread perception that septic DIC is most commonly associated with Gram-negative bacteria infection, Gram-positive bacteria – as well as other micro-organisms, including viruses and parasites (such as malaria) – may cause dramatic activation of blood coagulation, causing severe forms of DIC.9
Overall, the pathogenesis of DIC is characterised by simultaneous activation of haemostasis and fibrinolysis, resulting in extensive and persistent generation of thrombin and plasmin.10 However, studies in experimental models of sepsis have put forward the concept that thrombin generation might largely exceed that of plasmin. Convincing evidence also indicated that such an imbalance between coagulation and fibrinolysis might be due to increased levels of plasminogen activator inhibitor type 1 (PAI-1).11 A constellation of biological mechanisms has been advocated to trigger and/or boost DIC in patients with sepsis, including:
• increased thrombin generation mediated predominantly by activation of tissue factor/factor VIIa pathway and impaired function of physiological anticoagulant pathway (e.g. reduction of antithrombin levels, depression of the protein C pathway, inhibition of tissue factor pathway inhibitor);
• impaired fibrinolysis mediated by release of plasminogen activators from endothelial cells immediately followed by an increase in the plasma levels of PAI-1; and
• activation of the inflammatory pathway mediated by activated coagulation proteins and depression of the protein C pathway.2
While cytokines and inflammatory mediators can induce coagulation, thrombin and other serine proteases interact with protease-activated receptors on cell surfaces to boost inflammation. Furthermore, since activated protein C has an anti-inflammatory effect through its inhibition of endotoxin-induced production of tumour necrosis factor-α (TNF-α), interleukin (IL)-β, IL-6 and IL-8, depression of the protein C system may also result in a pro-inflammatory state.2 Taken together, this biological evidence is consistent with the hypothesis that septic DIC should be considered as a unique pathophysiological, biochemical and clinical entity in which inflammatory and coagulation pathways interplay in a sort of vicious circle (see Figure 1).

Laboratory Diagnostics in Septic Disseminated Intravascular Coagulation

The diagnosis of septic DIC is possible using a combination of laboratory tests for which simple diagnostic algorithms have now become available. However, these tests can be used for diagnosing and monitoring DIC only when at least two main requisites are fulfilled: identification of DIC at the earliest possible phase and availability in routine and, especially, urgent clinical settings.12 Patients with DIC have a low or rapidly decreasing platelet count, prolonged coagulation tests, low plasma levels of coagulation factors and inhibitors and increased markers of fibrin formation and/or degradation, such as D-dimer or fibrin degradation products (see Table 1). Therefore, a reliable approach to the diagnosis of DIC is the use of a simple scoring system based on the combination of routinely available coagulation tests.

Scoring Cards for Disseminated Intravascular Coagulation

The SSC on DIC of the ISTH has developed a four-parameter scoring card for DIC for ‘overt’ and ‘non-overt’ DIC. The scoring for overt DIC is as follows:
• platelet count: >100×109/l = 0, <100x109/l = 1, <50x109/l = 2; • elevated fibrin degradation products: no increase = 0, moderate increase = 2, strong increase = 3; • prothrombin time (PT) upper limit of reference range: <3 seconds = 0, >3 seconds = 1, >6 seconds = 2; and
• fibrinogen level: >100mg/dl = 0, <100mg/dl = 1.
An overall score of 5 is compatible with overt DIC.1 A five-year overview by the ISTH SSC on DIC has recently confirmed that a score of 5 or greater can reliably identify overt DIC with a sensitivity of 91% and a specificity of 97%.13 It was also shown that patients with overt DIC diagnosed according to the ISTH DIC score had a significantly higher risk of death and of developing septic shock. However, since more than 95% of sepsis patients have elevated fibrin-related markers, the DIC score is strongly dependent on prolongation of PT and platelet count.14
The Japanese Ministry of Health and Welfare (JMHW) established the diagnostic criteria for DIC in 1987. These criteria are also based on a scoring system relying on the presence of underlying disease, bleeding, organ failure and the results of global coagulation tests, and include:
• platelet count: ≤120×109/l = 1, ≤80×109/l = 2, ≤50×109/l = 3;
• elevated fibrin degradation products: ≥10μg/ml = 1, ≥20μg/ml = 2, ≥40μg/ml = 3;
• PT:≥1.25 = 1, ≥1.67 = 2; and
• fibrinogen levels: ≤150mg/dl = 1, ≤100 mg/dl = 2.
An overall score of ≥4 or ≥7 is compatible with DIC in patients with or without haematological malignancies, respectively.15 The rate of agreement in the diagnosis of DIC by ISTH and JMHW criteria was 67%; only 2% of non-DIC patients by JMHW criteria were diagnosed with overt DIC by ISTH criteria, suggesting that the ISTH criteria for overt DIC may include typical cases of DIC.16
The Japanese Association for Acute Medicine (JAAM) DIC Study Group recently announced new DIC diagnostic criteria for critically ill patients, reaffirming the reliability of using a four-parameter scoring card that includes:
• inflammatory response syndrome criteria: ≥3 = 1, 0–2 = 0;
• platelet count: <80x109/l or 50% decrease within 24 hours = 3, ≥80×109/l, <120x109/l or >30% decrease within 24 hours = 1 and >120×109/l = 0;
• PT:≥1.2 = 1, <1.2 = 0; and • fibrin/fibrinogen degradation products: ≥25 mg/l = 3, ≥10 and <25mg/dl = 1, <10 = 0.
An overall score of ≥4 is compatible with DIC.17 Two subsequent prospective surveys demonstrated the natural history of DIC patients diagnosed by the JAAM DIC diagnostic criteria in a critical care setting, highlighting progression from the JAAM DIC to the ISTH overt DIC,18 especially in patients with sepsis,19 thus enabling them to receive early treatment. More interestingly, a recent study by the JAAM DIC Study Group also showed that more than 50% of JAAM DIC patients with sepsis who died within 28 days could not be detected by ISTH DIC criteria during the initial three days.20

Global Tests of Haemostasis

The PT is a simple, rapid and relatively inexpensive haemostatic test that explores the extrinsic and common pathways of blood coagulation.21 Although its values have been reported to be prolonged in the vast majority of patients with DIC (up to 70%), the use of PT as a diagnostic test is questionable because elevations often occur in a later stage of the disease when the outcome of the patients may already be compromised.22 The activated partial thromboplastin time (APTT) is a global clotting test sensitive to several plasma inhibitors and acquired or inherited deficiencies of coagulation factors of the intrinsic and common pathway. Prolonged APTT values have been reported in up to 50% of patients with DIC, but in the other 50% they can be normal or even shortened (mirroring the acute-phase-induced increase of von Willebrand factor). Accordingly, its clinical usefulness is limited in the diagnostics of DIC; it certainly cannot be used to rule out the diagnosis, and overall it is even more unreliable than the PT.22 Fibrinogen levels often decline in patients with DIC due to massive consumption of the protein entrapped within the thrombi. However, the overall sensitivity of plasma fibrinogen levels for the diagnosis of DIC is low, since the protein is an additional well-recognised acutephase reactant and its levels are often within the normal range for a long period of time, especially in patients with severe infections. Thus, hypofibrinogenaemia is frequently detected only in very severe cases of DIC, or in the advanced stages of the disease.2,22 More important is the longitudinal comparison of fibrinogen values of the patient, because a sudden and dramatic drop often underlies massive consumption, as is commonplace in patients with DIC.2,22
In contrast to fibrinogen, platelet count is considered a very sensitive test in the diagnosis of DIC. Platelet count is strongly correlated with markers of thrombin generation, since thrombin-induced platelet aggregation is to a large extent responsible for platelet consumption. Moreover, platelet count is not influenced by the acute-phase response, so overall it is more reliable than fibrinogen testing. However, since the normal platelet count varies between 150 and 450×109/l, a single determination might be misleading; the longitudinal comparison of data may provide more valuable information in this setting. Many of the underlying conditions that are associated with DIC may in fact cause a low platelet count in the absence of DIC, such as severe local infections, malignancy or anticancer therapy. Accordingly, a continuous drop in the platelet count, mainly determined at intervals between one and four hours, underlies thrombin generation and the subsequent intravascular platelet aggregation. Conversely, a stable platelet count suggests that thrombin formation has stopped.2,22

Consumption of Natural Inhibitors

The natural anticoagulants, especially antithrombin and protein C, are frequently reduced in patients with DIC, and they also have prognostic significance.23,24 A decrease in plasma antithrombin levels below 50% of normal is strongly associated with increased mortality in patients with DIC.25 Wilson et al. observed that in surgical patients with sepsis, antithrombin levels below 70 and 65% are associated with 90 and 100% mortality, respectively.26 Accordingly, baseline antithrombin levels have the best prognostic value for prediction of subsequent death in patients affected by septic shock.27 A significant prognostic value of protein C concentrations in neutropenic patients affected by septic shock has also been reported.28 Although a significant decrease of natural inhibitors, such as antithrombin, protein C or both, can hence be considered valuable information for establishing a diagnosis of DIC and monitoring the clinical course of the disease, the ISTH SSC on DIC has recently concluded that there appears to be no added value in including their estimations within the conventional four-parameter scoring card.13 However, their measurement may be helpful in assessing severity of disease, monitoring the therapy and establishing the prognosis.29 In line with this hypothesis, it was recently shown that a lower initial antithrombin level in neonatal sepsis is associated with severe disease and increased mortality; therefore, its measurement may be useful in predicting clinical outcomes in this setting.30

Fibrin(ogen) Degradation Products

Several clinical studies have shown that elevations of fibrin(ogen) degradation products (FDPs), D-dimer and soluble fibrin monomers (sFMs) are highly sensitive but poorly specific for the diagnosis of DIC, and elevations of their values often precede overt DIC by several days.31 Depending on the assay and the cut-off chosen to distinguish normal and abnormal levels, their sensitivities range from approximately 90 to 100%.10 D-dimer testing has nowadays replaced other markers of fibrinolysis in clinical and laboratory practice for diagnosing a variety of thrombotic disorders.32 Moreover, at the 2003 meeting of the ISTH SCC on DIC, D-dimer was finally proposed as the ideal fibrin marker in the diagnostic algorithm for DIC.13 However, as is the case for other laboratory tests, the use of D-dimer testing alone is questionable. In fact, given that its high negative predictive value is counterbalanced by its poor positive predictive value, it can be used only within a rule-out strategy that incorporates several other clinical and laboratory parameters. Moreover, due to poor standardisation and insufficient harmonisation among the different commercial assays available on the market, the choice of the most predictive threshold for the diagnosis of DIC is crucial, as the different cut-offs are not interchangeable.32

Waveform Analysis

The APTT is the most common test of haemostasis performed in clinical laboratories, second only to the PT. Although abnormalities in the end-point of this test (e.g. prolongation of the clotting time) are conventionally used for detecting (and thereby reflect) quantitative and qualitative deficiencies in the intrinsic and common pathways of coagulation, the recent evidence of an atypical profile of clot formation in patients with haemostatic dysfunction has disclosed otherwise unexpected scenarios in monitoring anticoagulant therapy with unfractionated heparin and detecting inhibitors of blood coagulation.
An arbitrarily named ‘biphasic waveform’ was originally detected, when a decrease in plasma light transmittance before clot formation on the MDA-180 automated coagulation analyser was shown to be a hallmark of critically ill patients with DIC.33,34 Although the normal sigmoidal waveform pattern is characterised by an initial 100% light transmittance phase before clot formation, such biphasic patterns are instead sustained by an immediate, progressive decrease in light transmittance that occurs even in the pre-clotting phase. The definitive mechanisms underlying the biphasic waveform have not been definitely elucidated. However, it has been suggested that C-reactive protein (CRP), whose levels are persistently elevated in sepsis, may interact with very-low-density lipoproteins or intermediate-density lipoproteins to rapidly form a macroscopic precipitate upon recalcification of the plasma. These CRP– lipoprotein complexes can also be induced by incubating acute-phase serum containing elevated levels of CRP with serum from type III hyperlipidaemic patients.35 Whether CRP–lipoprotein complexes are an epiphenomenon of DIC, or whether they contribute to pathogenesis, is still controversial.
In 2002, it was reported that the biphasic waveform appears early in samples from patients who are later diagnosed with DIC by more conventional criteria.36 Further evidence corroborated this finding, also suggesting that this new APTT-derived parameter correlates with both the presence of DIC and overall mortality in patients with DIC. Matsumoto et al. showed that the prevalence of the biphasic waveform is as high as 87% (odds ratio 29.9) and 75% (odds ratio 19.0) in patients with septic DIC diagnosed by the ISTH and the JMHW scores, respectively. These findings led the authors to conclude that biphasic waveform is characterised by modest sensitivity (59.2% for the ISTH score; 47.9% for the JMWH score) but high specificity (95.4% for both scores).37 Similar diagnostic performances were reported in a further investigation, where biphasic waveform was observed in one-third of patients with a clinical suspicion of DIC and correlated well with the presence of disease (sensitivity 88%, specificity 97%). Remarkably, in nearly 20% of the patients, the APTT-biphasic-waveform-based diagnosis of DIC preceded that based on the traditional ISTH scoring system.38 Compared with other conventional parameters, biphasic waveform is characterised by superior prediction compared with CRP alone,39 whereas its combination with procalcitonin significantly increases the specificity of the latter test.40 Taken together, this evidence suggests that APTT waveform analysis may be a promising, inexpensive and rapid test in the diagnosis of severe sepsis (with both sensitivity and negative predictive value >90%), as well as for gathering useful information for the prognosis of septic patients, that can be used much earlier than traditional score systems41 provided that the MDA-180, the only analyser where this function has been detected, is available.

Inflammatory Biomarkers

For a better understanding of the immunological dysregulation in sepsis, several biomarkers are now available for routine and urgent diagnostics, including CRP, differential blood counting, the cytokines IL-6, IL-8, TNF-α, procalcitonin and the LPS-binding protein (LBP).42 However, only a few of these have a real impact throughout the managed care of patients with sepsis and therefore fulfil the clinical requirements.
Procalcitonin is a 116 amino acid protein with a sequence identical to that of the prohormone of calcitonin (32 amino acids). Under physiological conditions, hormonally active calcitonin is produced and secreted in the C cells of the thyroid gland after specific intracellular proteolytic procession of the prohormone procalcitonin. However, in severe bacterial infections and sepsis, extrathyroidal production of intact procalcitonin occurs, which is followed by secretion within the bloodstream.43 Basically, procalcitonin levels can help distinguish between bacteraemia and non-infectious inflammatory states accurately and quickly in critically ill patients, and its current use encompasses diagnosis and monitoring of therapy in patients with infections and systemic inflammation (values >0.5ng/ml generally indicate an acute infection accompanied by a systemic inflammatory reaction, whereas particularly high values are reported in severe bacterial infections and septic inflammation, severe sepsis or septic shock), differential diagnosis of inflammatory diseases and fever of unknown origin (e.g. acute pancreatitis), differential diagnosis of infectious microbial-induced fever versus non-bacterial fever (e.g. in immunosuppressed patients), differential diagnosis of acute organ rejection versus post-transplantation infection and prognostic information and clinical management in sepsis, septic shock and MOF. Additional diagnostic procedures can be implemented, or a treatment regimen changed or confirmed in septic patients, based on increasing or declining procalcitonin values.44 In a critically ill patient with clinical sepsis, Gram-negative bacteraemia could be associated with higher procalcitonin values than those found in Gram-positive bacteraemia, regardless of the severity of the disease.45 However, procalcitonin is of little use in diagnosing fungal (e.g. invasive aspergillosis, candidaemia), viral (e.g. cytomegalovirus) and severe intracellular infections (e.g. mycoplasma).
It should be noted that two recent meta-analyses of pooled data both concluded that procalcitonin cannot reliably differentiate sepsis from other non-infectious causes of systemic inflammatory response syndrome in critically ill adult patients, thus arguing against the widespread use of the procalcitonin test in critical care settings.46,47 Giamarellos-Bourboulis et al. earlier reported that procalcitonin can be regarded as an early prognostic marker of the advent of DIC and MOF, so its daily monitoring may be helpful in the follow-up of critically ill patients.48 Boussekey et al. also observed that procalcitonin levels were increased in patients with community-acquired pneumonia who developed infection-related DIC during their intensive care unit stay.49 Interestingly, Ucar et al. did not find any significant increase in the levels of TNF-α and serum amyloid A (SAA) in newborns with neonatal late-onset sepsis who developed DIC, but procalcitonin was markedly increased in all of these patients on days zero, four and eight.50
LBP is an acute-phase protein involved in the endotoxin-mediated immune response. Although the overall diagnostic performance of this test is comparable to that of procalcitonin, LBP has slow kinetics of induction and elimination, and the severity of the inflammatory response is not well diagnosed.51
ILs, especially IL-1 and IL-6, are biomarkers indicating the severity of the inflammatory response, but they are not specific for bacterial infection since they can be induced after surgery, autoimmune disorders, transplant rejection and viral infection. Immunosuppression also decreases the IL response. The kinetics of most ILs is also very fast; concentrations increase only briefly or intermittently and decline very quickly in sepsis, so their measurement is not superior to that of procalcitonin for the diagnosis of sepsis and may be unsuitable to monitor the clinical course of the disease.51,52 Finally, the measurements of most ILs is still challenging for a variety of pre-analytical/analytical reasons, and several instruments in the statistics laboratory are not equipped to deal with these tests.
The routine use of other traditional laboratory tests (e.g. leukocyte count, blood differential counting and CRP) is prompted by low cost, easy availability and historical practice rather than strong evidence. However, their reliability is hampered by a protracted response with late peak levels, low specificity compared with procalcitonin, especially in patients with MOF,49,53,54 and a reduced increase in patients undergoing steroid or other immunosuppressive therapies. Moreover, unlike procalcitonin, the dynamics of CRP and blood differential counting have limited prognostic implication.49,54

Conclusions

Although the contribution of laboratory diagnostics to the diagnosis of DIC is unquestionable, no single test result alone can definitely establish or rule out the disease. When approaching patients with suspected DIC it is therefore essential to consider a constellation of parameters, including clinical signs and symptoms, the identification of a potential underlying disease and, last but not least, the results of laboratory testing. When choosing among the armamentarium of tests that can be used to assist in the diagnosis, one should first consider that these may ultimately mirror changes in haemostatic function and keep pace with the critical nature of this condition.24 Global tests of haemostasis such as PT, APTT, fibrinogen and platelet count provide important evidence of activation of blood coagulation and, ultimately, consumption of coagulation factors, but their diagnostic efficiency is as yet questionable. Fibrinolytic markers (namely D-dimer) reliably reflect the extent of activation of both coagulation and fibrinolysis, so evidence of normal values can be reliably used to rule out the disease. The contribution of other tests of haemostasis, such as antithrombin and protein C, is as yet questionable. Decreased levels of these natural inhibitors are a marker of consumption coagulopathy and are frequently observed in patients with septic DIC, but they are not currently incorporated in any of the three widely used diagnostic algorithms. Among the inflammatory biomarkers, procalcitonin is currently regarded as the ideal candidate to differentiate the type of the infection and guide antibiotic therapy due to several advantages over other inflammatory markers, including earlier increase that is preserved in the presence of immunosuppressive medication, a better negative predictive value and a better correlation with outcome (e.g. mortality).52 However, its clinical usefulness in identifying and predicting the outcome of patients with DIC is circumstantial; therefore, larger studies in which this marker is evaluated against clinical outcome are needed. ■

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Giuseppe Lippi, Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degli Studi di Verona, Ospedale Policlinico GB Rossi, Piazzale Scuro, 10, 37134 Verona, Italy. E: ulippi@tin.it

Received

2009-04-02T00:00:00

References

  1. Taylor FB Jr, Toh CH, Hoots WK, et al., Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation, Thromb Haemost, 2001;86:1327–30.
  2. Franchini M, Lippi G, Manzato F, Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation, Thromb J, 2006;4:4.
  3. Kobayashi T, Terao T, Maki M, Ikenoue T, Diagnosis and management of acute obstetrical DIC, Semin Thromb Hemost, 2001;27:161–7.
  4. Barbui T, Falanga A, Disseminated intravascular coagulation in acute leukemia, Semin Thromb Hemost, 2001;27:593–604.
  5. Levi M, de Jonge E, van der Poll T, Sepsis and disseminated intravascular coagulation, J Thromb Thrombolysis, 2003;16:43–7.
  6. Zeerleder S, Hack CE, Wuillemin WA, Disseminated intravascular coagulation in sepsis, Chest, 2005;128: 2864–75.
  7. Opal SM, The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis, Int J Med Microbiol, 2007;297:365–77.
  8. Hardaway RM, Williams CH, Vasquez Y, Disseminated intravascular coagulation in sepsis, Semin Thromb Hemost, 2001;27:577–83.
  9. Levi M, van der Poll T, Coagulation in sepsis: all bugs bite equally, Crit Care, 2004;8:99–100.
  10. Horan JT, Francis CW, Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation, Semin Thromb Hemost, 2001;27:657–66.
  11. Hack CE, Fibrinolysis in disseminated intravascular coagulation, Semin Thromb Hemost, 2001;27:633–8.
  12. Toh CH, Laboratory testing in disseminated intravascular coagulation, Semin Thromb Hemost, 2001;27:653–6.
  13. Toh CH, Hoots WK; SSC on Disseminated Intravascular Coagulation of the ISTH, The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview, J Thromb Haemost, 2007;5:604–6.
  14. Voves C, Wuillemin WA, Zeerleder S, International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients, Blood Coagul Fibrinolysis, 2006;17:445–51.
  15. Kobayashi N, Maegawa K, Takada M, et al., Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan, Bibl Haematol, 1987;49:265–75.
  16. Wada H, Gabazza EC, Asakura H, et al., Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC, Am J Hematol, 2003;74:17–22.
  17. Gando S, Iba T, Eguchi Y, et al.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group, A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria, Crit Care Med, 2006;34:625–31.
  18. Gando S, Saitoh D, Ogura H, et al.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group, Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey, Crit Care Med, 2008;36:145–50.
  19. Gando S, Saitoh D, Ogura H, et al.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group, Disseminated intravascular coagulation (DIC) diagnosed based on the Japanese Association for Acute Medicine criteria is a dependent continuum to overt DIC in patients with sepsis, Thromb Res, 2009;123:715–18.
  20. Kushimoto S, Gando S, Saitoh D, et al.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma, Thromb Haemost, 2008;100:1099–1105.
  21. Favaloro EJ, Adcock DM, Standardization of the INR: how good is your laboratory’s INR and can it be improved?, Semin Thromb Hemost, 2008;34:593–603.
  22. Bick RL, Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations, Semin Thromb Hemost, 1998;24:3–18.
  23. de Jonge E, van der Poll T, Kesecioglu J, Levi M, Anticoagulant factor concentrates in disseminated intravascular coagulation: rationale for use and clinical experience, Semin Thromb Hemost, 2001;27:667–74.
  24. Levi M, Toh CH, Thachil J, Watson HG, Guidelines for the diagnosis and management of disseminated intravascular coagulation, Br J Haematol, 2009;145: 24–33.
  25. Wiedermann CJ, Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis, Crit Care, 2006;10:209.
  26. Wilson RF, Mammen EF, Robson MC, et al., Antithrombin, prekallikrein, and fibronectin levels in surgical patients, Arch Surg, 1986;121: 635–40.
  27. Fourrier F, Chopin C, Goudemand J, et al., Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies, Chest, 1992;101:816–23.
  28. Mesters RM, Helterbrand J, Utterback BG, et al., Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications, Crit Care Med, 2000;28:2209–16.
  29. Cauchie P, Cauchie Ch, Boudjeltia KZ, et al., Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital — meaning of the ISTH score system, fibrin monomers, and lipoprotein- C-reactive protein complex formation, Am J Hematol, 2006;81:414–19.
  30. Ersoy B, Prognostic Value of Initial Antithrombin Levels in Neonatal Sepsis, Indian Pediatr, 2007;44: 581–4.
  31. Wada H, Sakuragawa N, Mori Y, et al., Hemostatic molecular markers before the onset of disseminated intravascular coagulation, Am J Hematol, 1999;60: 273–8.
  32. Lippi G, Franchini M, Targher G, Favaloro EJ, Help me, Doctor! My D-dimer is raised, Ann Med, 2008;40: 594–605.
  33. Downey C, Kazmi R, Toh CH, Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation, Br J Haematol, 1997;98:68–73.
  34. Downey C, Kazmi R, Toh CH, Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis, Thromb Haemost, 1998;809:65–9.
  35. Toh CH, Samis J, Downey C, et al., Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca2+-dependent complex of C-reactive protein with very low density lipoprotein and is a novel marker of impending disseminated intravascular coagulation, Blood, 2002;100:2522–9.
  36. Nesheim M, Samis J, Walker J, et al., Lipoproteincomplexed C-reactive protein and the biphasic transmittance waveform in critically ill patients, Blood Rev, 2002;16(Suppl. 1):S15–S22.
  37. Matsumoto T, Wada H, Nishioka Y, et al., Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation, Clin Appl Thromb Hemost, 2006;12:185–92.
  38. Bakhtiari K, Meijers JC, de Jonge E, Levi M, Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation, Crit Care Med, 2004;32:2416–21.
  39. Toh CH, Ticknor LO, Downey C, et al., Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation, Intensive Care Med, 2003;29:55–61.
  40. Zakariah AN, Cozzi SM, Van Nuffelen M, et al., Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients, Crit Care Med, 2008;36: 1507–12.
  41. Chopin N, Floccard B, Sobas F, et al., Activated partial thromboplastin time waveform analysis: a new tool to detect infection?, Crit Care Med, 2006;34:1654–60.
  42. Herzum I, Renz H, Inflammatory markers in SIRS, sepsis and septic shock, Curr Med Chem, 2008;15: 581–7.
  43. Schneider HG, Lam QT, Procalcitonin for the clinical laboratory: a review, Pathology, 2007;39: 383–90.
  44. Becker KL, Snider R, Nylen ES, Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations, Crit Care Med, 2008;36:941–52.
  45. Charles PE, Ladoire S, Aho S, et al., Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria, BMC Infect Dis, 2008;8:38.
  46. Tang BM, Eslick GD, Craig JC, McLean AS, Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis, Lancet Infect Dis, 2007;7:210–17.
  47. Jones AE, Fiechtl JF, Brown MD, et al., Procalcitonin test in the diagnosis of bacteremia: a meta-analysis, Ann Emerg Med, 2007;50:34–41.
  48. Giamarellos-Bourboulis EJ, Mega A, Grecka P, et al., Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?, Intensive Care Med, 2002;28:1351–6.
  49. Boussekey N, Leroy O, Georges H, et al., Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit, Infection, 2005;33: 257–63.
  50. Ucar B, Yildiz B, Aksit MA, et al., Serum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin-1beta levels in neonatal late-onset sepsis, Mediators Inflamm, 2008;2008:737141.
  51. Meisner M, Biomarkers of sepsis: clinically useful?, Curr Opin Crit Care, 2005;11:473–80.
  52. Müller B, Schuetz P, Trampuz A, Circulating biomarkers as surrogates for bloodstream infections, Int J Antimicrob Agents, 2007;30(Suppl. 1):S16–S23.
  53. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J, Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS, Crit Care, 1999;3:45–50.
  54. Schuetz P, Christ-Crain M, Müller B, Biomarkers to improve diagnostic and prognostic accuracy in systemic infections, Curr Opin Crit Care, 2007;13: 578–85.

Further Resources

Share this Article
Related Content In Haematology
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72